Recent studies further demonstrate the protective role of pharmacological PHD inhibition by reducing ATF4-CHOP-mediated neuronal death and protecting against oxidative damage in models of neurodegeneration including Parkinson’s and Alzheimer’s disease [16–20], where neuronal loss is paramount. The gene discussed is ATF4; the disease is Parkinson disease.